Ajanta Pharma Limited , a prominent pharmaceutical company, has reported a significant development in its shareholding structure. Ravi Agrawal, a promoter of the company, has released the pledge on 10,50,000 equity shares, as disclosed in a recent regulatory filing.

Key Details of the Pledge Release

Regulatory Compliance

Ajanta Pharma has adhered to the regulatory requirements by making the necessary disclosures to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). This action aligns with the Securities and Exchange Board of India (SEBI) regulations, specifically under the substantial acquisition and takeover regulations.

Implications of Pledge Release

The release of pledged shares typically indicates a positive development for the company and its shareholders. It suggests that the promoter has been able to fulfill financial obligations or has found alternative means of financing, reducing the overall encumbrance on the company's shares.

Transparency in Corporate Governance

By promptly disclosing this information, Ajanta Pharma demonstrates its commitment to transparency and good corporate governance practices. Such disclosures help investors and market participants make informed decisions based on the latest changes in the company's shareholding pattern.

The regulatory filing includes detailed information about the share encumbrance release, as mandated by SEBI's substantial acquisition and takeover regulations. This level of disclosure ensures that all stakeholders have access to critical information about changes in the company's ownership structure.

Investors and market analysts may monitor any further developments or changes in the promoter shareholding pattern of Ajanta Pharma, as these can potentially impact the company's stock performance and overall market perception.

Ajanta Pharma , a specialty pharmaceutical formulation company, has announced Monday, November 10, 2025, as the record date for its first interim dividend payment. The company made this disclosure to the BSE and NSE stock exchanges, demonstrating its commitment to shareholder value.

Dividend Details

The Board of Directors of Ajanta Pharma have approved a first interim dividend for the financial year 2026. Key details of the dividend are as follows:

Financial Performance

The dividend announcement comes on the heels of Ajanta Pharma's financial performance for the second quarter and first half of FY 2026:

• Q2 FY 2026 revenue from operations increased by 14% to Rs. 1,354.00 crore
• Q2 FY 2026 profit after tax (PAT) grew by 20% to Rs. 260.00 crore
• H1 FY 2026 revenue from operations rose by 14% to Rs. 2,656.00 crore
• H1 FY 2026 PAT increased by 12% to Rs. 516.00 crore

Segment Performance

Ajanta Pharma's growth was driven by performances across its business segments:

Market Position

According to IQVIA MAT September 2025 data, Ajanta Pharma's India branded generics performance exceeded the Indian Pharmaceutical Market (IPM) growth by 32%. The company showed growth in key therapeutic areas:

Investor Information

Investors and shareholders should take note of the November 10, 2025 record date to be eligible for the interim dividend payment.

This dividend announcement, coupled with the company's financial performance, underscores Ajanta Pharma's commitment to delivering value to its shareholders while maintaining growth across its business segments.